LUCENT-2, a multicenter, randomized, double-blind, placebo-controlled maintenance study of mirikizumab in patients who have completed the 12-week LUCENT-1 induction study is ongoing.
UC is a chronic inflammatory disease of the large intestine, also referred to as the colon, that affects the lining of the colon and may cause small sores, or ulcers, to form.i This inflammation can cause abdominal pain, frequent and urgent trips to the bathroom, bloody stools and incontinence.1 UC can cause significant and debilitating disruptions in daily life. Millions of people live with UC globally.2
'There is a continued need for additional treatments that can provide people living with ulcerative colitis relief from their most challenging symptoms,' said
In LUCENT-1, mirikizumab met the primary endpoint of clinical remission at Week 12 compared to placebo (p
(C) 2021 Electronic News Publishing, source